Analysts' Actions: JNJ FNFG WLL CA VRTX

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

CA ( CA) was downgraded from buy to neutral at Mizuho. $25 price target. CEO could change the product development process, which might cause near-term disruptions, Mizuho said.

F5 Networks ( FFIV) was downgraded to hold at TheStreet Ratings.

First Niagara ( FNFG) was upgraded to outperform at KBW. $10.50 price target. New CEO could prove to be an inflection point for the company, Keefe, Bruyette & Woods said.

Johnson & Johnson ( JNJ) was downgraded to neutral from overweight at J.P. Morgan. $83 price target. Valuation call.

Juniper Networks ( JNPR) was upgraded at Argus to buy from hold. $22 price target. Earnings recovery is finally underway, Argus said.

L-3 Communications ( LLL) was downgraded at J.P. Morgan to underweight from neutral. Company is most at risk from sequestration cuts, J.P. Morgan said.

Vail Resorts ( MTN) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Valuation call, as the stock is up 44% over the past year, Credit Suisse said.

Northrop Grumman ( NOC) was upgraded at J.P. Morgan to equal-weight from underweight. Valuation call, J.P. Morgan said.

Public Service ( PEG) was downgraded at Argus to hold from buy. Valuation call, as the stock is approaching the previous $35 price target, Argus said.

RDA Microelectronics ( RDA) was downgraded to hold at TheStreet Ratings.

Vertex Pharmaceuticals ( VRTX) was initiated with a hold rating at Canaccord. Valuation call, based on a $55 price target.

Whiting Petroleum ( WLL) was upgraded to overweight at J.P. Morgan. Valuation call, given the company's better outlook, J.P. Morgan said.

STOCK COMMENTS/EPS CHANGES

Apple ( AAPL) estimates were increased at Canaccord Genuity through 2014. Company is seeing higher iPhone 4 and 4S sales, and new products should continue to drive demand. Buy rating and $600 price target.

AstraZeneca ( AZN) estimates were cut at Leerink Swann through 2014. Cautious feedback for Fostamatinib lowers the chance for FDA approval, Leerink Swann said.

Daimler ( DDAIF) price target and estimates were reduced at UBS. First-quarter guidance was worse than expected on weak markets (Germany) and wholesale sales, driving a reduction in earnings estimates, said UBS. The price target goes to $70.22.

Hanesbrands ( HBI) price target and estimates were increased at Citigroup. The price target was increased to $54 after the company initiated a dividend which will attract new investors, said Citigroup. Earnings estimates for 2013 were increased given a better-than-expected first quarter result, Citigroup added.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Some of Trump's NFL Owner Friends Side With Players in Dispute With President

The Best Companies for Women

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'